Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.46 |
| ▸ | FNTB | P49356 | 10/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 9/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20188037 | 1.00 | FNTA (0.46) | FNTAFNTBPGGT1BCTSCHDAC6 | |
| SCHEMBL20188420 | 0.89 | LTA4H (0.46) | HDAC6HDAC1TLR2NPY1R | |
| SCHEMBL20188418 | 0.89 | LTA4H (0.46) | HDAC6HDAC1TLR2NPY1R | |
| SCHEMBL20187724 | 0.86 | ALDH1A1 (0.43) | HDAC6HDAC1TLR2NPY1R | |
| SCHEMBL20187725 | 0.86 | ALDH1A1 (0.43) | HDAC6HDAC1TLR2NPY1R | |
| SCHEMBL20188352 | 0.84 | HDAC6 (0.43) | HDAC6HDAC1NPY1R | |
| SCHEMBL20187756 | 0.84 | HDAC6 (0.43) | HDAC6HDAC1NPY1R | |
| SCHEMBL20187757 | 0.84 | HDAC6 (0.43) | HDAC6HDAC1NPY1R | |
| SCHEMBL20188793 | 0.81 | GPR88 (0.42) | HDAC6HDAC1 | |
| SCHEMBL20188791 | 0.81 | GPR88 (0.42) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | claimed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | claimed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | claimed |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | disclosed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | GRIN3A, GRIN1, GRM3 | FNTA 1801/4885FNTB 4376/4885PGGT1B 4138/4885 |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | GRIN3A, GRIN1, GRM3 | FNTA 1801/4885FNTB 4376/4885PGGT1B 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.